BFM
QNCX icon

Boothbay Fund Management’s Quince Therapeutics QNCX Stock Holding History

Boothbay Fund Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-71
Closed -$1.29M – 2154
2021
Q3 		$1.29M Buy
+71
New +$1.13M 0.04% 635

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Boothbay Fund Management's QNCX Position: Q4 2020 in Review

Boothbay Fund Management sold out of Quince Therapeutics (QNCX) in Q4 2020, closing a stake of 23 shares — an estimated $204K sold.

Boothbay Fund Management first reported a position in QNCX in Q3 2020 and held it in 1 quarter. The position peaked at $230K in Q3 2020. 84 funds tracked by Wall St. Rank hold QNCX as of Q4 2020.

  • Boothbay Fund Management reported no remaining Quince Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 23 Quince Therapeutics shares in Q4 2020, an estimated $204K.
  • Boothbay Fund Management first reported a position in Quince Therapeutics in Q3 2020 and held it in 1 quarter.
  • Boothbay Fund Management's Quince Therapeutics position peaked at $230K in Q3 2020.
  • 84 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2020.

Based on Boothbay Fund Management's 13F filing for Q4 2020, filed 12 Feb 2021.